Navigation Links
Vion Pharmaceuticals Announces Initiation of a Phase I/II Trial of Cloretazine(R) (VNP40101M) in Combination with Temodar(R) in Adult Brain Tumors
Date:9/17/2007

of the mechanisms of resistance in malignant gliomas is AGT. We are hoping that we can deplete the level of AGT with Temodar(R) and that the combination of agents will improve anti-tumor responses and outcomes. To date there is no standard therapy for malignant gliomas that recur; if we can increase progression- free and overall survival with this combination, we will be able to help patients."

Ann Cahill, Vice President, Clinical Development, said, "Despite decades of research, there has been little progress in the treatment of malignant gliomas which recur after primary therapy. We are pleased to support Dr. Raizer's study of Cloretazine(R) (VNP40101M) in this patient population."

Cloretazine(R) (VNP40101M) has previously been evaluated as a single agent in a Phase II clinical trial in patients with recurrent glioblastoma multiforme (Badruddoja MA et al, 2007 Neuro-Oncology; 9: 70-74). In addition, a Phase I trial of Cloretazine(R) (VNP40101M) as a single agent in pediatric brain tumors was recently completed. Data from this trial were presented at the American Society of Clinical Oncology Annual Meeting in June 2007.

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia. Clinical trials of Cloretazine(R) (VNP40101M) in small cell lung cancer and adult brain tumors are also being conducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. In preclinical studies, Vion is also evaluating VNP40541, a hypoxia-selective compound, and hydrazone compounds. The Company is seek
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... According to a new market research report ... Ablation Catheter (Cryoablation, RF, Microwave), Lab Devices (Mapping, Recording, ... Global Forecasts to 2019 ", published by MarketsandMarkets, the Electrophysiology ... by 2019 with a CAGR of around 10.3% during ... Browse   90   ma rket data T ...
(Date:3/27/2015)... N.J. , March 27, 2015  Johnson & Johnson ... Shareholders at 10 a.m. (Eastern Time) on Thursday, April 23, ... N.J. Investors and other interested parties ... visiting the Company,s website at www.jnj.com and clicking ... from the meeting will be made available a few hours ...
(Date:3/26/2015)... HOUSTON , March 26, 2015  The ... of a study independently conducted by the Department ... Japan have been published. ... compared 5-fluorouracil hepatic arterial infusion as post-operative adjuvant ... colorectal metastasis of the liver. ...
Breaking Medicine Technology:Electrophysiology (EP) Market Worth $4.73 Billion by 2019 2Electrophysiology (EP) Market Worth $4.73 Billion by 2019 3Electrophysiology (EP) Market Worth $4.73 Billion by 2019 4
... recognition awarded to top-rated abstracts , CAMBRIDGE, Mass., ... the development of novel products to deliver RNAi-based ... that the company,s TransKingdom RNA interference ( tk ... poster sessions featuring late-breaking research at the American ...
... to Evaluate Safety of CCL2-LPM for Inflammatory Kidney ... Inc. announced today that patient dosing has commenced ... company,s lead compound, CCL2-LPM, for the treatment of ... Pharmaceuticals U.S.A. is developing novel chemokine-enzyme fusion protein ...
Cached Medicine Technology:Cequent tkRNAi Technology to be Presented at the Centennial Meeting of the American Association for Cancer Research 2Cequent tkRNAi Technology to be Presented at the Centennial Meeting of the American Association for Cancer Research 3Osprey Pharmaceuticals U.S.A., Inc. Initiates Phase Ib Clinical Trial in IgA Nephropathy 2Osprey Pharmaceuticals U.S.A., Inc. Initiates Phase Ib Clinical Trial in IgA Nephropathy 3
(Date:3/28/2015)... NV (PRWEB) March 28, 2015 How ... is a growing field in orthopaedic medicine. While diagnostic ... tear to confirm the pain etiology, research presented today ... AOSSM ) Specialty Day suggests that pain relief from ... arthroscopic hip surgery. , “Our study looked to ...
(Date:3/28/2015)... 28, 2015 Andrew Hawley of Vintage Rock ... psychedelic concert posters. The Who and the Doors played together ... 2, 1968. According to Hawley, “The Who toured the United ... and college campuses. Perhaps the most famous Who poster was ... and the Doors on August 2, 1968 at the Singer ...
(Date:3/28/2015)... March 28, 2015 The "Petrick ... of sustainable health. After 18 years of research and ... professional UFC contenders, Dr. Jon Petrick is excited to ... Just some of the immediate benefits of this radical ... increased levels of strength of the immune system, faster ...
(Date:3/28/2015)... Robles, CA (PRWEB) March 28, 2015 ... restoration specialists , this week released a report about ... the symptoms of asthma sufferers, and according to recent ... children. , According to the Environmental Protection Agency, ... develop asthmatic reactions. Breathing in mold may trigger asthma ...
(Date:3/27/2015)... Deer, Alberta (PRWEB) March 27, 2015 In ... until then, prevented her from working, Monica K. arrived at ... in the mending department quiet, defensive and scared. The owners ... Placement & Support Services (EPSS) to offer jobs to ... does take patience and a willingness to begin with the ...
Breaking Medicine News(10 mins):Health News:Pain Injections for Hip Arthroscopy Patients May Not Predict Surgical Outcomes 2Health News:Avid Collector from Vintage Rock Posters, Inc. Announces His Search For Original 1960's Who Psychedelic Concert Posters. 2Health News:Celebrity Chiropractor Jon Petrick to Release Sustainable Health System this Summer 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 3Health News:Red Deer Uniforms Shop Celebrates 3rd Year Sewing Hope for the Challenged 2Health News:Red Deer Uniforms Shop Celebrates 3rd Year Sewing Hope for the Challenged 3
... alternative remedies more likely to misuse prescribed drugs, suffer ... Many asthma patients who use herbal remedies experience increased ... shows. , Researchers followed 326 asthma patients for 33 ... herbal remedies and used prescribed inhaled corticosteroids (ICS) less ...
... , , Wounded Veterans Face Growing ... Feb. 5 Today, Iraq and Afghanistan ... organization representing veterans of the wars in Iraq and ... bureaucratic roadblocks, lengthy waits for care, and complicated disability systems facing ...
... authors are nationally known informatics leaders and members of ... Feb. 2010 issue of Health Affairs and ... delivery in an increasingly information-driven era of health care ... role that information technology, and the health informatics work ...
... ... , ... 5, 2010 -- Aspen Dental ( www.aspendent.com ), one of the largest and fastest-growing providers ... in 2009, opening 44 new dental offices for an expansion of nearly 25 percent. The ...
... children, teens stable longer , THURSDAY, Feb. 4 (HealthDay News) ... type 1 diabetes could benefit by using an artificial pancreas ... levels during sleep and help them control their disease. , ... The Lancet , examined use of an artificial pancreas ...
... ... coronary artery bypass clinical study, based on a protocol reviewed by the U.S. Food ... with the FDA as part of the company,s submission for U.S. regulatory approval of ... (PRWEB) ...
Cached Medicine News:Health News:Herbals Not the Answer for Asthma, Study Shows 2Health News:New IAVA Report Reveals Red Tape Facing Veterans in the Military and VA Health Care and Disability Systems 2Health News:New IAVA Report Reveals Red Tape Facing Veterans in the Military and VA Health Care and Disability Systems 3Health News:New IAVA Report Reveals Red Tape Facing Veterans in the Military and VA Health Care and Disability Systems 4Health News:Informatics experts contribute to special Health Affairs edition on e-health in the developing world 2Health News:Informatics experts contribute to special Health Affairs edition on e-health in the developing world 3Health News:Aspen Dental Opens 44 New Offices, Welcomes 340,000 New Patients in 2009 2Health News:Aspen Dental Opens 44 New Offices, Welcomes 340,000 New Patients in 2009 3Health News:Artificial Pancreas Helps Type 1 Diabetics During Sleep 2Health News:Pluromed Announces Completion of Enrollment in LeGoo™ Cardiac Bypass Clinical Trial 2Health News:Pluromed Announces Completion of Enrollment in LeGoo™ Cardiac Bypass Clinical Trial 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: